Integer (NYSE:ITGR) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Integer (NYSE:ITGR) from a strong sell rating to a hold rating in a research report report published on Monday,Zacks.com reports.

ITGR has been the topic of several other research reports. Citigroup upped their price target on Integer from $92.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Truist Financial lifted their price objective on Integer from $97.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. KeyCorp reissued an “overweight” rating and set a $104.00 price objective on shares of Integer in a report on Tuesday. Weiss Ratings restated a “hold (c)” rating on shares of Integer in a research report on Thursday, June 18th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $97.00 target price (up from $87.00) on shares of Integer in a research note on Friday, May 1st. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $97.00.

Integer Stock Performance

Shares of Integer stock opened at $96.05 on Monday. The company has a debt-to-equity ratio of 0.77, a current ratio of 3.75 and a quick ratio of 2.38. The firm has a 50 day simple moving average of $91.97 and a 200 day simple moving average of $87.81. Integer has a fifty-two week low of $62.00 and a fifty-two week high of $116.31. The firm has a market cap of $3.26 billion, a P/E ratio of 23.95, a P/E/G ratio of 2.29 and a beta of 0.64.

Integer (NYSE:ITGR) last posted its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.21 by ($0.01). The firm had revenue of $439.58 million for the quarter, compared to analyst estimates of $426.48 million. Integer had a return on equity of 12.83% and a net margin of 7.64%.The firm’s quarterly revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the company posted $1.31 EPS. Integer has set its FY 2026 guidance at 5.830-6.400 EPS. Sell-side analysts predict that Integer will post 6.04 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integer

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Irenic Capital Management LP bought a new stake in shares of Integer in the 4th quarter valued at $99,109,000. Alliancebernstein L.P. lifted its holdings in Integer by 885.1% during the second quarter. Alliancebernstein L.P. now owns 1,106,091 shares of the medical equipment provider’s stock worth $136,016,000 after acquiring an additional 993,810 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Integer by 1,141.6% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 819,046 shares of the medical equipment provider’s stock worth $72,076,000 after acquiring an additional 753,081 shares in the last quarter. Millennium Management LLC grew its stake in Integer by 3,350.2% in the fourth quarter. Millennium Management LLC now owns 677,108 shares of the medical equipment provider’s stock valued at $53,106,000 after acquiring an additional 657,483 shares during the period. Finally, J. Goldman & Co LP acquired a new position in Integer in the fourth quarter valued at about $40,531,000. 99.29% of the stock is owned by institutional investors.

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.